thecardiologyadvisor.com6d
Aficamten Effective for Obstructive Hypertrophic Cardiomyopathy
A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.
KMC Hospital saves German priest with advanced cardiac care
KMC Hospital in Mangaluru successfully treats Rev Fr Wolfgang Leonhard, a German priest, diagnosed with hypertrophic obstructive cardiomyopathy and complete heart block. The cardiology team implanted ...
ETF Daily News6d
LianBio (NASDAQ:LIAN) Stock Price Up 2.5% – Should You Buy?
The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex ...
Cytokinetics: Strategic Growth and Strong Financial Positioning Drive Buy Rating
Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Cytokinetics (CYTK – Research Report), reducing the price target to ...
Business Insider2d
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM), ...
Bristol Myers Squibb Springs Ahead of Chicago Conference
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place this week ...
MM&M6d
Eyeing drug launch in 2025, Cytokinetics rolls out HCM awareness campaign
The San Francisco-based drugmaker recently launched a campaign to educate healthcare professionals (HCP) about hypertrophic ...
Cytokinetics, Incorporated: Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Na ...
ahajournals.org4d
Abstract 4139929: The mechanisms of Mid-ventricular obstruction in patients with hypertrophic cardiomyopathy: Insight from an echocardiographic study
Background:Mid-ventricular obstruction (MVO) is a rare subtype of hypertrophic cardiomyopathy (HCM), but it is associated with severe symptoms and worse clinical outcomes. Whereas the mechanisms of ...
Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...
ahajournals.org4d
Abstract 4140102: Changes in EQ-5D-5L with Aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM): the SEQUOIA-HCM Trial
Introduction: In patients with obstructive hypertrophic cardiomyopathy (oHCM), the SEQUOIA-HCM trial demonstrated that aficamten, a next-in-class cardiac myosin inhibitor, improved exercise capacity, ...